Form 8-K - Current report:
SEC Accession No. 0001213900-25-038442
Filing Date
2025-05-01
Accepted
2025-05-01 16:09:59
Documents
15
Period of Report
2025-04-28
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0240327-8k_adial.htm   iXBRL 8-K 31946
2 LETTER FROM MARCUM LLP, DATED APRIL 30, 2025, ADDRESSED TO THE SECURITIES AND EX ea024032701ex16-1_adial.htm EX-16.1 2656
3 GRAPHIC ex16-1_001.jpg GRAPHIC 13718
  Complete submission text file 0001213900-25-038442.txt   231152

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adil-20250428.xsd EX-101.SCH 3005
5 XBRL LABEL FILE adil-20250428_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE adil-20250428_pre.xml EX-101.PRE 22352
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0240327-8k_adial_htm.xml XML 3799
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

EIN.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 25903159
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)